What is ViewsML?
ViewsML is at the forefront of applying artificial intelligence to critical areas of cancer care, including treatment, diagnosis, and research. Their core technology focuses on precision medicine and the detection of biomarkers, enhancing the efficiency of clinical workflows. By providing virtual diagnostics that deliver results in mere seconds, ViewsML significantly cuts down the time and expense associated with conventional methods. The company serves a broad spectrum of clients, from preclinical and translational research to clinical research and contract research organizations, all with the overarching goal of improving patient outcomes and expediting project completion. Their deep learning capabilities are instrumental in enabling better patient stratification and generating richer data sets across diverse biomarkers and therapeutic areas.
How much funding has ViewsML raised?
ViewsML has raised a total of $4.9M across 1 funding round:
Seed
$4.9M
Seed (2026): $4.9M with participation from RiSC Capital, Debiopharm, Wutif, Wittington Ventures, and Continuum Ventures
Key Investors in ViewsML
RiSC Capital
RiSC Capital is a Canadian deep tech venture capital fund specializing in early-stage startups, providing strategic guidance to foster growth in deep tech innovations.
Debiopharm
Debiopharm Investment, the investment arm of Debiopharm Group, focuses on safeguarding capital and generating financial returns for its subsidiaries through private equity and other investments.
Wutif
WUTIF is a venture capital fund that invests in early-stage technology startups in British Columbia, offering significant tax incentives to investors and targeting various technology sectors including life sciences.
What's next for ViewsML?
With the recent major strategic investment, ViewsML is poised for accelerated growth and market expansion. The substantial capital injection, part of its $4.9M total funding, will likely be directed towards scaling its AI platform, enhancing its diagnostic capabilities, and broadening its reach within the global healthcare and research markets. This funding round, characterized as a major enterprise-level funding, suggests a transition towards broader commercialization and strategic partnerships. ViewsML's focus on improving patient outcomes and reducing healthcare costs positions it as a key player in the evolving landscape of AI-driven oncology.
See full ViewsML company page
